Saturday 17 October 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
Dividend growth for three consecutive years.
9.59
0.07
+0.74%
Follow RGC
| Jun '17 | Jun '19 | Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.12 | 0.12 | 0.02 | 28.46 | 19.15 | 41.91 | 7.39 | 10.77 |
Net Debt/EBITDA |
— | 0.62 | 0.48 | 0.04 | 2.20 | 1.93 | 1.80 | 1.33 | 1.22 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 1.00 | 0.89 | 0.57 | 0.71 | 0.85 | 0.93 | 0.87 | 0.66 |
Capex/Depreciation |
— | — | (12.40) | 0.00 | (5.20) | (0.09) | (0.02) | (1.97) | 0.00 |
| — | 17.42% | 36.19% | 40.51% | (113.82%) | (40.39%) | (42.58%) | (54.81%) | (128.52%) | |
| — | (321.41%) | (214.55%) | (315.35%) | (81.11%) | (38.32%) | (40.85%) | (50.50%) | (114.25%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (717.14%) | (923.47%) | (1,149.68%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | 21.27% | 30.43% | 32.15% | (44.91%) | (51.25%) | (53.36%) | (80.46%) | (89.76%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.01) | (0.01) | (0.02) |
Cash per Share |
— | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.02 | 0.01 | 0.03 |
Shareholders Equity per Share |
— | 0.00 | (0.01) | (0.01) | 0.04 | 0.02 | 0.02 | 0.01 | 0.03 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | (0.01) | (0.01) | 0.04 | 0.02 | 0.02 | 0.01 | 0.03 |
Free Cash Flow |
— | (0.39) | (0.84) | (0.77) | (6.05) | (4.99) | (4.01) | (3.27) | (7.70) |
Working Capital |
— | (1.84) | (2.78) | (4.27) | 15.87 | 11.01 | 7.92 | 4.24 | 12.90 |
Capital Expenditures |
— | — | (0.12) | — | (0.78) | (0.03) | (0.01) | (0.15) | — |
Net Current Asset Value |
— | (1.84) | (2.78) | (4.27) | 15.51 | 10.99 | 7.89 | 4.01 | 12.84 |
| Other line items | |||||||||
Quick Ratio |
— | 0.12 | 0.12 | 0.01 | 28.41 | 19.06 | 41.12 | 7.38 | 10.75 |
Depreciation/Fixed assets |
— | — | 0.09 | 0.32 | 0.21 | 0.66 | 2.16 | 0.36 | 0.60 |
Cash ROIC |
— | 24.51% | 37.30% | 19.48% | (18.05%) | (21.18%) | (24.77%) | (33.48%) | (27.94%) |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.01) | (0.01) | (0.02) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Assets |
— | 0.12 | 0.38 | 0.43 | 9.18 | 15.32 | 10.53 | 7.10 | 10.24 |
Average Common Equity |
— | (2.24) | (2.24) | (3.32) | 6.54 | 14.54 | 10.10 | 6.54 | 9.10 |
Capex to Sales |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 9 Oct 2026